ized PC-type lymphadenopathy, accompanied by generalized symptoms, has been recognized as multicentric CD (MCD) (2) . To our knowledge, intracranial space-occupying CDis extremely rare. Although meningeal involvement of the central nervous system (CNS)is one of the typical manifestations of MCD, the CNSmass lesion due to MCDhas not been reported. Seven cases of intracranial unicentric CDhave been reported and six of them were initially misdiagnosed as meningioma (3, 4) . This is the first reported case of MCD, the initial presentation of which was an intracranial tumor. A 48-year-old man visited a neurosurgeon because of numbness around his right upper lip. A brain computerized tomography (CT) revealed a well-circumscribed mass in the left temporo-parietal area with surrounding edema (Fig. 1 A) . Aleft craniotomy revealed that the tumor was firmly attached to the dura mater and infiltrated the skull. The tumor consisted of markedly thickened dura and numerous secondary lymphoid follicles with large and polymorphous germinal centers, wide lymphoid cuffs, and dense infiltration of plasma cells in the interfollicular areas. Someof the germinal centers were penetrated with a few capillary vessels, which contained no hyaline deposits (Fig. IB) . Bone marrow of the skull overlaying the tumor showedsimilar changes. Wecould not detect any clonal proliferation of the plasma/B cells using immunohistochemical stainings or polymerase chain reaction for IgH chains. Based on these findings, several pathologists agreed that the tumor should be diagnosed as PC-type CD. After surgical removal, the neurological symptom disappeared completely but a year later, a follow-up magnetic resonance imaging (MRI) showed evidence of recurrence. After a second craniotomy, the patient was referred to the hematologists of our hospital for treatment due to the presence of a residual tumor. Erythrocyte sedimentation rate was 19 mmper hour. C-reactive protein; 0.24 mg/dl (normal;^0.25), total protein; 7.2 g/ dl, albumin; 3.9 g/dl, IgG; 2,174 mg/dl, IgA; 235 mg/dl, IgM; 126 mg/dl, interleukin-6 (IL-6); 81.1 pg/ml (normal;^4.0), soluble IL-6 receptor (SIL-6R); 34.4 ng/ml (normal; 14.0-46.0). Anabdominal CTrevealed a mass lesion in the right renal hilum, which surrounded the renal pelvis. A CT-guided needle biopsy was performed and the pathology of the specimen was compatible with PC-type CD. After the second craniotomy, he was treated with 30 Gy irradiation for residual brain and renal tumors. After the irradiation, the tumors completely disappeared and the IL-6 level decreased to 34.7 pg/ml. To date, there is no evidence of further recurrence. Wetreated the first case with intracranial and retroperitoneal space-occupying MCD.We diagnosed the patient as having MCDbecause of intracranial and retroperitoneal tumors. It remains unsolved whether the intracranial and retroperitoneal tumors occurred simultaneously or independently because neither chest nor abdominal CTs were taken on the first admission. Since MCDusually causes generalized symptoms, it is of interest that the patient had no generalized symptomsother than the intracranial mass as well as normal SIL-6Rvalues despite high IL-6 values. IL-6 is a pleiotropic cytokine with a wide range of biologic activities and it is thought to play a central role in the pathogenesis of CD/MCD(5). The observation that this patient had high IL-6 and normal SIL-6R suggests the possibility of the presence of aberrant IL-6 signal transduction. Wedid not administer corticosteroids or antineoplastic agents because he had no generalized symptoms. Although we have treated only one patient, we feel that surgical excision followed by irradiation maycure intracranial space-occupying MCD.
